Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BRD3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BRD3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BRD3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BRD3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BRD3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BRD3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BRD3 | insertion | Frame_Shift_Ins | rs768970491 | c.71_72insC | p.Glu25GlyfsTer51 | p.E25Gfs*51 | Q15059 | protein_coding | | | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
BRD3 | deletion | Frame_Shift_Del | rs763134487 | c.71delN | p.Pro24ArgfsTer24 | p.P24Rfs*24 | Q15059 | protein_coding | | | TCGA-DI-A0WH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | deletion | Frame_Shift_Del | | c.644delC | p.Pro215GlnfsTer28 | p.P215Qfs*28 | Q15059 | protein_coding | | | TCGA-E6-A2P8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
BRD3 | deletion | Frame_Shift_Del | rs763134487 | c.71delC | p.Pro24ArgfsTer24 | p.P24Rfs*24 | Q15059 | protein_coding | | | TCGA-E6-A2P8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
BRD3 | deletion | Frame_Shift_Del | rs763134487 | c.71delC | p.Pro24ArgfsTer24 | p.P24Rfs*24 | Q15059 | protein_coding | | | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRD3 | insertion | Frame_Shift_Ins | rs768970491 | c.71_72insC | p.Glu25GlyfsTer51 | p.E25Gfs*51 | Q15059 | protein_coding | | | TCGA-EY-A1GD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | deletion | Frame_Shift_Del | rs763134487 | c.71delN | p.Pro24ArgfsTer24 | p.P24Rfs*24 | Q15059 | protein_coding | | | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRD3 | deletion | Frame_Shift_Del | rs763134487 | c.71delC | p.Pro24ArgfsTer24 | p.P24Rfs*24 | Q15059 | protein_coding | | | TCGA-EY-A1H0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
BRD3 | deletion | Frame_Shift_Del | rs763134487 | c.71delC | p.Pro24ArgfsTer24 | p.P24Rfs*24 | Q15059 | protein_coding | | | TCGA-EY-A548-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRD3 | deletion | Frame_Shift_Del | rs763134487 | c.71delC | p.Pro24ArgfsTer24 | p.P24Rfs*24 | Q15059 | protein_coding | | | TCGA-EY-A5W2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ABBV-744 | ABBV-744 | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ALPRAZOLAM | ALPRAZOLAM | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | PMID26924192-Compound-102 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ESTAZOLAM | ESTAZOLAM | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 252827533 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | PMID26924192-Compound-104 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | Pyrrolo-pyrrolone derivative 1 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 187051822 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | L-655708 | CHEMBL52030 | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 404859011 | | |